Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VI Technologies gets US nod for INACTINE trials:

This article was originally published in Clinica

Executive Summary

The US FDA has given VI Technologies the go-ahead to start its pivotal phase III clinical trial programme for its INACTINE pathogen reduction red blood cell system. Researchers will assess the safety and effectiveness of red blood cells in two concurrent studies - one involving patients requiring acute transfusion support, and another involving those who need chronic transfusion support. "The trial designs support our goal of commercialising a system that combines broad pathogen inactivation, red cell purity, storage for 42 days and indications for use consistent with licensed red blood cells," said John Barr, the Watertown, Massachusetts firm's president and CEO.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT067218

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel